G

GARNERO M

Last name: GARNERO M

2019 (v1)

Publication

Metadata-only

Outcomes after single-cycle rituximab monotherapy in patients with anti-MAG polyneuropathy: A bi-center experience with an average follow-up of 11 years

Benedetti L Garnero M Demichelis C

Rituximab is efficacious in myelin-associated glycoprotein (MAG) polyneuropathy, but the question on timing of retreatments is open. We studied 21 anti-MAG polyneuropathy patients who responded to a first cycle of rituximab, were followed-up for an average of 11.2 years, and were retreated only when relapsing. Baseline serum B-cell-activating...

Uploaded on: April 14, 2023
2020 (v1)

Publication

Metadata-only

Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy.

Massa F Zuppa A Pesce G

No description

Uploaded on: February 7, 2024